In the Medicinal Chemistry Lab, expanded upon my previous research project, studying plasma protein binding of GalNAc conjugates to further understand siRNA plasma pharmacokinetics. Performed EMSA gel electrophoresis, used the Biacore SPR system, conducted HLPC Analysis, used gel imaging software, manipulated large amounts of raw data, presented my findings to RNAi Discovery Group, and participated in a poster session. Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 3 programs in late-stage clinical development.

Responsible for overseeing 18 first year students, as well as planning and implementing social, educational, and personal development oriented programs for a community of 559 first year students.The mission of the Office of Residential Life is to create a respectful, healthy, inclusive, and safe living community for our residents. We are committed to integrating the Ignatian tradition into the formation of each student by connecting their intellectual, ethical, religious, and spiritual lives through a multiplicity of programs and services. Our role in this formation is to promote the academic mission of the University, encourage responsible and ethical behaviors, engage residents in conversations regarding diversity, and to create safe, well-managed learning environments where students can seek the greater good.

In the Medicinal Chemistry Lab, conducted a research project studying oligonucleotide-plasma protein binding interactions for in vitro assay development. Performed EMSA gel electrophoresis, used gel imaging software, manipulated large amounts of raw data, presented my findings to RNAi Discovery Group, and participated in a poster session. Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 3 programs in late-stage clinical development.

In the Cell Pharmacology lab of the Cardiovascular and Metabolism Disease Area, performed tasks in basic molecular biology including, RNA extraction and qPCR (investigating the role of genetic mutations on adipogenesis); and plasmid purification, vector manipulation using Gibson Assembly, and DNA sequencing (assay development for compound screening).The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. We collaborate across scientific and organizational boundaries, with a focus on powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients.